Translational advances in pancreatic ductal adenocarcinoma therapy
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
[HTML][HTML] MDSC: Markers, development, states, and unaddressed complexity
Myeloid-derived suppressor cells (MDSCs) are one of the most discussed biological entities
in immunology. While the context and classification of this group of cells has evolved …
in immunology. While the context and classification of this group of cells has evolved …
Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer
NG Steele, ES Carpenter, SB Kemp, VR Sirihorachai… - Nature Cancer, 2020 - nature.com
Pancreatic ductal adenocarcinoma (PDA) is characterized by an immune-suppressive tumor
microenvironment that renders it largely refractory to immunotherapy. We implemented a …
microenvironment that renders it largely refractory to immunotherapy. We implemented a …
The β1-adrenergic receptor links sympathetic nerves to T cell exhaustion
CD8+ T cells are essential components of the immune response against viral infections and
tumours, and are capable of eliminating infected and cancerous cells. However, when the …
tumours, and are capable of eliminating infected and cancerous cells. However, when the …
Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches
Cancer is one of the leading causes of death worldwide. Several treatments are available for
cancer treatment, but many treatment methods are ineffective against multidrug-resistant …
cancer treatment, but many treatment methods are ineffective against multidrug-resistant …
Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
NA Ullman, PR Burchard, RF Dunne… - Journal of Clinical …, 2022 - ascopubs.org
The rising incidence and persistent dismal 5-year overall survival of pancreatic ductal
adenocarcinoma (PDAC) highlight the need for new effective systemic therapies …
adenocarcinoma (PDAC) highlight the need for new effective systemic therapies …
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
M Orth, P Metzger, S Gerum, J Mayerle, G Schneider… - Radiation …, 2019 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is considered non-immunogenic, with trials
showing its recalcitrance to PD1 and CTLA4 immune checkpoint therapies (ICTs). Here, we …
showing its recalcitrance to PD1 and CTLA4 immune checkpoint therapies (ICTs). Here, we …
[HTML][HTML] Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer
Here, we utilized spontaneous models of pancreatic and lung cancer to examine how
neoantigenicity shapes tumor immunity and progression. As expected, neoantigen …
neoantigenicity shapes tumor immunity and progression. As expected, neoantigen …
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
T Zhang, Y Ren, P Yang, J Wang, H Zhou - Cell Death & Disease, 2022 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a prominent extracellular
matrix (ECM) deposition and poor prognosis. High levels of ECM proteins derived from …
matrix (ECM) deposition and poor prognosis. High levels of ECM proteins derived from …